Highlights MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/02/2026 GMT			5-day change	1st Jan Change
5.740 ^USD	-1.54%		-7.57%	+1.23%

02-09	MannKind Enrolls First Patient in Study Evaluating Afrezza Inhaled Insulin in Youth	MT
02-09	MannKind announces first patient enrolled in Inhale-1st pediatric study evaluating Afrezza® for youth with newly-diagnosed type 1 diabetes (T1d)	RE

Highlights

02-09	Mannkind Corporation Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza®? for Youth with Newly-Diagnosed Type 1 Diabetes	CI
01-26	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
01-26	MannKind Corporation Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching from Multiple Daily Injections or Insulin Pump Mealtime Therapy	CI
01-26	MannKind announces FDA approval of updated Afrezza label providing starting dose guidance when switching from multiple daily injections (MDI) or insulin pump mealtime therapy	RE
12-23	MannKind Corporation Shares FUROSCIX®? Business Updates	CI
12-01	MannKind announces U.S. FDA accepts for review its supplemental new drug application (sNDA) of Furoscix Readyflow(TM) autoinjector	RE
12-01	MannKind Corporation Announces U.S. FDA Accepts for Review its Supplemental New Drug Application of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Kidney Disease	CI
11-10	MannKind Corporation Announces Discontinuing its Phase 3 Clinical Trial Evaluating Nebulized Inhalation Suspension of Clofazimine	CI
11-05	MannKind Shares Rise After Q3 Beat	MT
11-05	MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	MannKind's Q3 Non-GAAP Net Income, Revenue Rise	MT
11-05	Biopharma MannKind's Q3 revenue up 17%	RE
11-05	Earnings Flash (MNKD) MannKind Corporation Reports Q3 Revenue $82.1M, vs. FactSet Est of $80.2M	MT
11-05	Earnings Flash (MNKD) MannKind Corporation Posts Q3 Adjusted EPS $0.07 per Share, vs. FactSet Est of $0.03	MT
13/10/25	Mannkind Corporation Announces U.S. Fda Accepts for Review Its Supplemental Biologics License Application for Inhaled Insulin in Children and Adolescents Aged 4-17 Years Living with Diabetes	CI
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
07/10/25	MannKind Corporation completed the acquisition of scPharmaceuticals Inc..	CI
07/10/25	MannKind Completes Acquisition of scPharmaceuticals	MT
07/10/25	MannKind completes acquisition of ScPharmaceuticals, accelerating revenue growth in cardiometabolic care	RE
27/08/25	MannKind Corporation Enters into First Amendment to Global License and Collaboration Agreement with United Therapeutics Corporation	CI
27/08/25	MannKind, United Therapeutics to Develop Second Inhaled Therapy	MT
25/08/25	MannKind Corporation entered into a definitive agreement to acquire scPharmaceuticals Inc. for approximately $290 million.	CI
25/08/25	MannKind to Acquire scPharmaceuticals for Up to $360 Million	MT
25/08/25	MannKind to acquire scPharmaceuticals	RE
06/08/25	MannKind Q2 Adjusted Earnings Flat, Revenue Rises	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Highlights

Filters